Effects of Osteogenic Growth Peptide C-terminal Pentapeptide and Its Analogue on Bone Remodeling in an Osteoporosis Rat Model

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2023 Mar 6

PMID 36874360

Authors

Yuhang Ma

Ying Zhang

Yi Lin

Xiaoying Ding

Yuntao Zhang

Affiliations

Soon will be listed here.

Abstract

This study aimed to explore the effects of osteogenic growth peptide C-terminal pentapeptide (G36G), and its analog G48A on bone modeling in rats with ovariectomy-induced osteoporosis. Ovariectomized rats were administered PBS (OVX group), risedronate (RISE group), G36G combined with risedronate (36GRI group), G36G (G36G group), or G48A (G48A group). The sham-operation rats (SHAM group) were administered PBS. Serum osteocalcin and IGF-2 levels in the SHAM, OVX, G36G, G48A, and RISE groups were observably lower than the 36GRI group ( < 0.01) and the bone mineral density of the entire femur, distal metaphysis, and lumbar L1-L4 in the 36GRI group were notably increased ( < 0.05). The bending energy of the 36GRI group was prominently higher than the other groups ( < 0.05). Other features measured in the study that provided significant outcomes was the ratio of femora ash weight/dry weigh, parameters of trabecular bone volume (TBV)/total tissue volume, TBV/sponge bone volume, mean trabecular plate thickness, mean trabecular plate space, bone surface, parameters of sfract(s) and sfract(d), tetracycline-labeled, and osteoid surfaces. Bone loss in ovariectomized rats may be partially inhibited by G36G and G48A. A combination treatment with G36G and risedronate may be an effective intervention for osteoporosis.

References

Turner A . Animal models of osteoporosis--necessity and limitations. Eur Cell Mater. 2003; 1:66-81. DOI: 10.22203/ecm.v001a08. View

Ensrud K, Crandall C . Osteoporosis. Ann Intern Med. 2017; 167(3):ITC17-ITC32. DOI: 10.7326/AITC201708010. View

Lelovas P, Xanthos T, Thoma S, Lyritis G, Dontas I . The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008; 58(5):424-30. PMC: 2707131. View

Nirwan N, Nikita , Sultana Y, Vohora D . Liposomes as multifaceted delivery system in the treatment of osteoporosis. Expert Opin Drug Deliv. 2021; 18(6):761-775. DOI: 10.1080/17425247.2021.1867534. View

Tsiridis E, Upadhyay N, Giannoudis P . Molecular aspects of fracture healing: which are the important molecules?. Injury. 2007; 38 Suppl 1:S11-25. DOI: 10.1016/j.injury.2007.02.006. View

Morrison A, Fan T, Sen S, Weisenfluh L . Epidemiology of falls and osteoporotic fractures: a systematic review. Clinicoecon Outcomes Res. 2013; 5:9-18. PMC: 3536355. DOI: 10.2147/CEOR.S38721. View

Chen Y, Bab I, Mansur N, MUHLRAD A, Shteyer A, Gavish H . Structure-bioactivity of C-terminal pentapeptide of osteogenic growth peptide [OGP(10-14)]. J Pept Res. 2000; 56(3):147-56. DOI: 10.1034/j.1399-3011.2000.00763.x. View

Vanella L, Kim D, Asprinio D, Peterson S, Barbagallo I, Vanella A . HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone. 2009; 46(1):236-43. PMC: 2818489. DOI: 10.1016/j.bone.2009.10.012. View

Brager M, Patterson M, Connolly J, Nevo Z . Osteogenic growth peptide normally stimulated by blood loss and marrow ablation has local and systemic effects on fracture healing in rats. J Orthop Res. 2000; 18(1):133-9. DOI: 10.1002/jor.1100180119. View

10.

Jee W, Yao W . Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact. 2005; 1(3):193-207. View

11.

Fei Q, Cui D, Chen T, Chen Z . Synthetic Osteogenic Growth Peptide Stimulates Osteoblast Osteogenic Activity and Enhances Fracture Healing in Rabbits. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002; 33(4):415-420. View

12.

Barnsley J, Buckland G, Chan P, Ong A, Ramos A, Baxter M . Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res. 2021; 33(4):759-773. PMC: 8084810. DOI: 10.1007/s40520-021-01817-y. View

13.

Lewiecki E, Binkley N, Bilezikian J . Treated Osteoporosis Is Still Osteoporosis. J Bone Miner Res. 2019; 34(4):605-606. DOI: 10.1002/jbmr.3671. View

14.

Khan M, Cheung A, Khan A . Drug-Related Adverse Events of Osteoporosis Therapy. Endocrinol Metab Clin North Am. 2017; 46(1):181-192. DOI: 10.1016/j.ecl.2016.09.009. View

15.

Zhou S, Huang G, Chen G . Synthesis and biological activities of drugs for the treatment of osteoporosis. Eur J Med Chem. 2020; 197:112313. DOI: 10.1016/j.ejmech.2020.112313. View

16.

Fei Q, Guo C, Xu X, Gao J, Zhang J, Chen T . Osteogenic growth peptide enhances the proliferation of bone marrow mesenchymal stem cells from osteoprotegerin-deficient mice by CDK2/cyclin A. Acta Biochim Biophys Sin (Shanghai). 2010; 42(11):801-6. DOI: 10.1093/abbs/gmq086. View

17.

Nollet M, Santucci-Darmanin S, Breuil V, Al-Sahlanee R, Cros C, Topi M . Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy. 2014; 10(11):1965-77. PMC: 4502694. DOI: 10.4161/auto.36182. View

18.

Singh S, Kumar D, Lal A . Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women. J Clin Diagn Res. 2015; 9(8):RC04-7. PMC: 4576601. DOI: 10.7860/JCDR/2015/14857.6318. View

19.

Gabet Y, Muller R, Regev E, Sela J, Shteyer A, Salisbury K . Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone. 2004; 35(1):65-73. DOI: 10.1016/j.bone.2004.03.025. View

20.

Zuo Y, Xiong Q, Li Q, Zhao B, Xue F, Shen L . Osteogenic growth peptide (OGP)-loaded amphiphilic peptide (NapFFY) supramolecular hydrogel promotes osteogenesis and bone tissue reconstruction. Int J Biol Macromol. 2021; 195:558-564. DOI: 10.1016/j.ijbiomac.2021.12.028. View